Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1531 to 1545 of 1688 results for carers

  1. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    Discontinued [GID-TA10965]

    Technology appraisal guidance
    Discontinued

  2. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    Discontinued [GID-TA10958]

    Technology appraisal guidance
    Discontinued

  3. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued [GID-TA10963]

    Technology appraisal guidance
    Discontinued

  4. The OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic joint revision (MIB13)

    NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic

    Medtech innovation briefing
    Published
    19 November 2014

  5. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    In development [GID-TA11357] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy TS ID 11801

    Discontinued [GID-TA11180]

    Technology appraisal guidance
    Discontinued

  7. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued [GID-TA11396]

    Technology appraisal guidance
    Discontinued

  9. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued [GID-TA10072]

    Technology appraisal guidance
    Discontinued

  10. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued [GID-TA10527]

    Technology appraisal guidance
    Discontinued

  11. Service delivery models:- Which models of service delivery are effective and cost-effective for older people with social care needs and multiple long-term conditions?

    include social care- and health-related quality of life, satisfaction, carer's health, number of unpaid care hours provided and health...

    Research recommendation
    Published
    11 December 2015

  12. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued [GID-TA10377]

    Technology appraisal guidance
    Discontinued

  13. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    In development [GID-TA11109] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development [GID-TA11265] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development [GID-TA11401] Expected publication date: TBC

    Technology appraisal guidance
    In development